After hitting a regulatory roadblock in 2022, Sanofi’s consumer healthcare business Opella has secured the FDA’s blessing to ...

Physician's Choice, a U.S. maker of supplements and probiotics, is exploring a sale that could value the company at over $500 ...

Sanofi’s (NASDAQ:SNY) consumer healthcare unit Opella announced Tuesday that the U.S. FDA has lifted a clinical hold on a ...

The US FDA has removed the clinical hold on a trial of Cialis (tadalafil) by Sanofi's consumer healthcare business, Opella.

Sanofi says the deal announced today will make it the world's number one consumer health company, with expected revenues of around €5.1 billion in 2015 ($5.61 billion) and a global market share ...

The FDA has warned Sanofi about a series of “significant” manufacturing problems, including contamination, at a key facility ...

Sanofi's Consumer Healthcare division, Opella, announced that the U.S. Food and Drug Administration has lifted a clinical hold on its ...

Sanofi (SNYNF – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Graham Parry from Bank ...

Clarius Group LLC lifted its holdings in shares of Sanofi (NASDAQ:SNY – Free Report) by 11.9% in the fourth quarter, ...

Within the atopic dermatitis (AD) field, Sanofi has been developing the IRAK4 degrader SAR444656 (KT-474) in collaboration ...